Brought to you by 
Bayer receives global license to Compugen’s cancer immunotherapeutics
20 Sep 2018
Executive Summary
For the second time, Compugen Ltd. (Israeli drug discovery company that trades on Nasdaq) and Bayer HealthCare LLC are teaming up. This time, the Big Pharma is getting global rights to Compugen’s cancer antibodies targeting two immune checkpoint regulators that are critical in immunosuppression.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com